Table 1 Effects on tumor growth and metastases
Items | Treatment groups | P value | ||||
|---|---|---|---|---|---|---|
Control (n = 10) | DOX (n = 11) | PDOX (n = 12) | ||||
Value | Inhibition ratio☆ | Value | Inhibition ratio☆ | |||
Liver tumor growth | ||||||
Tumor weight (mg) | 6657.4 ± 1312.9*,§ | 3860.0 ± 1023.6 | 42.0% | 3757.6 ± 603.5 | 43.6% | * <0.001 vs DOX § <0.001 vs PDOX |
Tumor volume (mm3) | 4965.2 ± 2112.4*,§ | 2526.9 ± 1360.1 | 49.1% | 2313.2 ± 675.7 | 53.4% | * <0.05 vs DOX § <0.001 vs PDOX |
TW/BW ratio | 27.94 ± 4.10*,§ | 18.28 ± 4.12 | 34.5% | 18.10 ± 3.18 | 35.2% | * <0.001 vs DOX § <0.001 vs PDOX |
AFP level (ng/mL) | 97.27 ± 34.22*,§ | 24.69 ± 12.09 | 74.6% | 22.31 ± 13.42 | 77.1% | * <0.001 vs DOX § <0.001 vs PDOX |
ePCI | 9 ± 2*,§ | 6 ± 2 | 33.3% | 6 ± 2 | 33.3% | * <0.05 vs DOX § <0.05 vs PDOX |
Tumor metastases | ||||||
Mediastinal LN meta | 70.0% (7/10) | 63.6% (7/11) | 9.1% | 33.3% (4/12) | 52.4% | >0.05 |
Lung meta | 100% (10/10) *,§ | 63.6% (7/11)# | 36.4% | 33.3% (4/12) | 66.7% | * <0.05 vs DOX § <0.05 vs PDOX #<0.05 vs PDOX |
Diaphragm meta | 90% (9/10) | 72.7% (8/11) | 19.2% | 50% (6/12) | 44.4% | >0.05 |
Intrahepatic meta | 30% (3/10) | 27.3% (3/11) | 9.0% | 50% (6/12) | −66.7% | >0.05 |
Spleen ligament meta | 70% (7/10) | 36.4% (4/11) | 48.0% | 41.7% (5/12) | 40.4% | >0.05 |
Heptogastric ligament meta | 90% (9/10) | 90.9% (10/11) | −1.0% | 83.3% (10/12) | 7.4% | >0.05 |
Renal ligament meta | 40.0% (4/10) | 36.4% (4/11) | 9.0% | 58.3% (7/12) | −45.8% | >0.05 |
Adrenal meta | 10.0% (1/10) | 0.0% (0/11) | 100% | 0.0% (0/12) | 100% | >0.05 |
Mesenteric meta | 90.0% (9/10) | 81.8% (9/11) | 9.1% | 58.3% (7/12) | 35.2% | >0.05 |
Retroperitoneal LN meta | 80.0% (8/10) *,§ | 27.3% (3/11) | 65.9% | 16.7% (2/12) | 79.1% | * <0.05 vs DOX § <0.05 vs PDOX |
Abdominal wall meta | 80.0% (8/10) | 45.5% (5/11) | 43.1% | 66.7% (8/12) | 16.6% | >0.05 |
Bloody ascites | 50.0% (5/10) | 9.1% (1/11) | 81.8% | 25.0% (3/12) | 50.0% | >0.05 |